Duavive (oestrogens conjugated;bazedoxifene)
- Region
- 🇪🇺 EU
- Active substance
- oestrogens conjugated;bazedoxifene
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Postmenopause
- CHMP opinion
- Thu 23 Oct 2014
- EU approval
- Tue 16 Dec 2014
- Application
- EMEA/H/C/002314
- ATC
- G03CC07
- Official record
- www.ema.europa.eu
Indication
Duavive is indicated for: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The experience treating women older than 65 years is limited.
Regulatory milestones
No milestones recorded in the last year.
Follow Duavive
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.